西利宾抑制肝细胞中酸盐的产生和分泌,从而逆转肝纤维化
Xule Yang1, Yunge Lou1, Huan Li1
1Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Archives of pharmacal research
|July 31, 2025
概括
西利宾通过减少线粒体中糖酸盐的积累和阻止其释放来对抗肝纤维化. 这种作用抑制了激活的肝星细胞,为肝纤维化提供了新的治疗策略.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝纤维化是一个全球性的健康问题,其机制尚未完全理解.
- 西利宾是已知的肝纤维化治疗剂,但其精确的作用方式需要阐明.
研究的目的:
- 为了研究氨酸减轻由胆缺乏,高脂肪饮食 (CDAHFD) 引起的肝纤维化所产生的分子机制.
- 探索线粒体新陈代谢的作用,特别是酸盐的积累,在肝纤维化和silybin的治疗作用.
主要方法:
- 给小鼠了一种CDAHFD,以诱导肝脏脂肪和纤维化.
- 对小鼠肝脏线粒体进行了代谢和脂质分析.
- 使用siRNA.RNA实现了CRLS1的淘汰.
- 进行了肝细胞和LX-2细胞激活试验.
主要成果:
- 在CDAHFD养的小鼠中,西利宾治疗逆转了线粒体代谢异常,并减少了糖酸盐的积累.
- 西利宾恢复了线粒体膜脂,增强了CRLS1的表达,并改善了糖酸脱酶 (SDH) 的活性.
- 西利宾通过降低MCT1载体的调节来抑制酸盐流量,从而抑制了LX-2细胞的激活.
结论:
- 西利宾通过抑制线粒体中糖酸盐的产生及其细胞外释放来缓解MASH诱导的肝纤维化,从而使肝脏星状细胞失活.
- 准糖酸盐代谢是一种有前途的治疗途径,可以对抗肝纤维化进展.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...


